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Abstract: Children with chronic kidney disease (CKD) are at high risk of anemia, an important
risk factor for cardiovascular disease and poor quality of life. The present study used baseline
data from the Korean cohort study for Outcome in patients With Pediatric Chronic Kidney Disease
(KNOW-PedCKD). A Total of 437 patients was included in the analyses excluding missing data.
The characteristics of patients with and without anemia and those of patients with and without iron
deficiency were compared. Logistic regression analysis and Pearson correlation were conducted
to evaluate associated risk factors and correlations in children with CKD. Anemia in children with
CKD was associated with older age, low body weight and body mass index (BMI) z-score, birth age,
preceding glomerulonephritis, decreased estimated glomerular filtration rate (eGFR), low levels of
serum albumin and calcium, high levels of serum intact parathyroid hormone (iPTH), and serum
phosphorus. Anemia was correlated positively with changes in the BMI z-score, body weight, and
serum albumin and cholesterol levels, but correlated negatively with serum calcium, iPTH, ferritin
levels, and transferrin saturation. Iron deficiency in children with CKD was associated with young
age, low hemoglobin and serum ferritin levels, high BMI z-scores, and low levels of serum iPTH.
This is the first nationwide cohort study of anemia in Korean children with CKD and the first
prospective pediatric CKD cohort study in Asia. The study results demonstrated that anemia and iron
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deficiency are affected by various factors, including age, BMI, and levels of serum iPTH. To improve
the retrospective outcome of affected children, it is important to understand the effect of each of
these factors and to attempt an early intervention to prevent anemia and iron deficiency by regular
measurement of these parameters in children at risk.
Keywords: anemia; iron deficiency; chronic kidney disease
1. Introduction
Anemia is a major complication in children with chronic kidney disease (CKD). Data from the
North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) revealed the prevalence
of anemia in children with CKD, ranging from 73 to 93%, depending on the CKD stage [1]. Among
children with CKD, anemia is an important risk factor for the development and progression of
cardiovascular disease, including left ventricular hypertrophy [2,3]. In addition, anemia negatively
affects the quality of life of patients and their caregivers [4,5].
The chronic inflammatory state in patients with CKD results in decreased erythropoiesis in the
bone marrow, reduced production of erythropoietin (EPO) in the kidneys, and impaired iron absorption
and mobilization due to increased production of hepcidin in the liver. Uremia, oxidative stress, and
nutritional deficiencies also contribute to anemia in CKD [6]. Therefore, although therapeutic targets
involving hemoglobin and iron levels are controversial, use of an erythropoiesis-stimulating agent
(ESA) and iron supplementation are key approaches to the management of anemia in CKD patients [7,8].
However, treatment of anemia in children with CKD is known to be less effective than that in adults [9],
and studies of anemia and iron deficiency are limited due to the small numbers of pediatric patients
with CKD.
The objectives of this study were to examine the characteristics of patients with anemia and iron
deficiency among children with CKD and to identify associated risk factors and correlations using
baseline data from the Korean cohort study for Outcome in patients With Pediatric Chronic Kidney
Disease (KNOW-PedCKD).
2. Materials and Methods
2.1. Study Design and Population
The KNOW-PedCKD study is a nationwide observational prospective cohort study of pediatric
CKD patients with CKD stages 1–5 recruited from seven major pediatric nephrology centers in Korea.
Details on the study design and objectives have been published previously [10]. For the current analysis,
we included subjects enrolled from April 2011 to February 2016 (n = 437). A total of 437 patients
was included in the analysis. If the individual tests have missing data, they were excluded in the
final analysis.
2.2. Clinical and Laboratory Measurements
CKD was defined and staged according to the Kidney Disease Improving Global Outcomes
(KDIGO) criteria [7]. For patients enrolled in the KNOW-PedCKD study, the estimated glomerular
filtration rate (eGFR) was calculated using the bedside Chronic Kidney Disease in Children (CKiD)
formula [11]. Data on medical history and medication use were collected through a self-administered
questionnaire. Anemia was defined as hemoglobin below the 5th percentile for age/sex or treatment
with an erythropoiesis-stimulating agent (ESA) [7,12]. Iron deficiency was defined as serum ferritin
<100 ng/mL and transferrin saturation <20% [7,8]. Hypertension was defined as the average value
of the systolic and/or diastolic BP measurements above the 95th percentile for age, sex, and height.
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The presence of comorbidity included heart failure, arrhythmia, urinary tract infection, diabetes,
retinopathy, sensorineural hearing loss, developmental delay, and metabolic syndrome.
2.3. Statistical Analyses
Categorical variables expressed as percentages were compared between groups with the
Chi-square test and Fisher’s exact test. Continuous variables were expressed as a mean ± standard
deviation and analyzed by the Kruskal–Wallis test. A logistic regression analysis was conducted to
determine the odds ratios (ORs) and confidence intervals (CIs) of associated risk factors for anemia
and iron deficiency in the cohort. The correlations among characteristics of anemia in the cohort were
analyzed with a Pearson r correlation. All statistical analyses were performed using SAS statistical
software (SAS system for Windows, version 9.4; SAS institute, Cary, NC, USA).
3. Results
3.1. Baseline Characteristics of Overall CKD Cohort
The demographic characteristics and clinical manifestations of patients with CKD are shown
in Table 1. The mean age of the patients was 9.5 ± 5.3 years, and most patients were found to be
in the middle 10s (43.9%). Among the CKD patients, male patients were more frequent than female
patients regardless of age (n = 299 versus n = 138). The most common disease leading to CKD was
renal hypoplasia (41.4%), while 66 patients had kidney dysplasia with/out vesico-ureteral reflux (VUR)
(15.1%), and 27.7% had glomerulonephritis. Overall, 27.2% of patients were in CKD stage 2, while a
minority (3.9%) had CKD stage 5 in a pre-dialysis state.




Age (years) 9.5 ± 5.3
0–2 years 43 (9.8)
2–6 years 77 (17.6)
6–12 years 125 (28.6)
12–17 years 192 (43.9)
Sex (male/female) 299/138
Disease preceding CKD
Primary glomerulopathy * 61 (14.0)
Secondary glomerulopathy * 60 (13.7)
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Table 1. Baseline demographics of the chronic kidney disease (CKD) patient cohort.  
Variable 
Total Patients (%) 
(n = 437)  
Age (years) 9.5 ± 5.3 
0–2 years 43 (9.8) 
2–6 years 77 (17.6) 
6–12 years 125 (28.6) 
12–17 years 192 (43.9) 
Sex (male/female) 299/138 
Disease preceding CKD   
Primary glomerulopathy * 61 (14.0) 
Secondary glomerulopathy * 60 (13.7) 
Kidney dysplasia with/out vesico-ureteral reflux 66 (15.1) 
Hypoplasia 181 (41.4) 
Other 69 (15.8) 
CKD stages   
I 79 (18.1) 
II 119 (27.2) 
IIIa ※ 74 (16.9) 
IIIb ※ 71 (16.3) 
IV 77 (17.6) 
V 17 (3.9) 
Birth weight (kg)  3.0 ± 0.7 
Birth age (weeks)  38.3 ± 3.1 
Disease duration (years) † 5.7 ± 4.7 
Duration of aggravated renal function (years) ‡ 2.9 ± 3.4 
Numerical values are reported as n (%); CKD, chronic kidney disease; n, number of patients. * More 
detailed data are described in supplementary Table S1; ※ CKD stage III is divided into subgroup 
stage IIIa and IIIb according to the eGFR (estimated glomerular filtration rate), stage IIIa is an eGFR 
between 45 and 59 and Stage 3b is an eGFR between 30 and 44; † Disease duration refers to the years 
between the date of the baseline data collection and the CKD diagnosis date; ‡ Duration of aggravated 
renal function means the years between the date of the baseline data collection and the date of onset 
of the preceding disease to CKD. 
74 (16.9)
IIIb
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Birth weight (kg) 3.0 ± 0.7
Birth age (weeks) 38.3 ± 3.1
Disease duration (years) † 5.7 ± 4.7
Duration of aggravated renal function (years) ‡ 2.9 ± 3.4
Numerical values are reported as n (%); CKD, chronic kidney disease; n, number of patients. * More detailed data
are described in supplementary Table S1;
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3.2. CKD Patients with Anemia
Characteristics of the CKD patients with and without anemia are listed in Table 2. Overall, older
age (p < 0.001), glomerulonephritis as a preceding disease (p < 0.001), higher CKD stages (p < 0.001),
higher diastolic blood pressure (DBP) (p = 0.029), lower body weight (p = 0.036), proteinuria (p < 0.001),
and use of a renin-angiotensin system inhibitor (p = 0.002) were significantly associated with CKD
patients with anemia, compared to those without. CKD patients with anemia were treated with
erythropoietin (EPO)-stimulating agents (21.6%, p = 0.001) and supplemental iron therapy (36.3%,
p = 0.001), and showed significantly lower ferritin levels (p < 0.001) than those without anemia. There
were no significant differences in sex distribution, platelet counts, systolic blood pressure, or transferrin
saturation according to the presence of anemia.
Table 2. Comparisons of characteristics of patients with anemia in the CKD cohort analysis.
Variable Patients with Anemia(n = 172)
Patients without Anemia
(n = 261) P Value
Age (years) 172 261 <0.001 ††
0–2 years 11 (6.4) 28 (10.7)
2–6 years 17 (9.9) 60 (23.0)
6–12 years 49 (28.5) 76 (29.1)
12–17 years 95 (55.2) 97 (37.2)
Sex (male/female) 119/53 175/86 0.641 ††
Disease preceding CKD 150 228 <0.001 ††
Glomerulonephritis 49 (32.7) 30 (13.2)
Non-glomerulonephritis 101 (67.3) 198 (86.8)
CKD stages 172 261 <0.001 ††
I 8 (4.7) 71 (27.2)
II 26 (15.1) 92 (35.2)
IIIa
J. Clin. Med. 2019, 8, x FOR PEER REVIEW  3 of 13 
 
2.3. Statistical Analyses 
Categorical variables expressed as percentages were compared between groups with the Chi-
square test and Fisher’s exact test. Continuous variables were expressed as a mean ± standard 
deviation and analyzed by the Kruskal–Wallis test. A logistic regression analysis was conducted to 
determine the odds ratios (ORs) and confidence intervals (CIs) of associated risk factors for anemia 
and iron deficiency in the cohort. The correlations among characteristics of anemia in the cohort were 
analyzed with a Pearson r correlation. All statistical analyses were performed using SAS statistical 
software (SAS system for Windows, version 9.4; SAS institute, Cary, NC). 
3. Results 
3.1. Baseline Characteristics of Overall CKD Cohort 
The demographic characteristics and clinical manifestations of patients with CKD are shown in 
Table 1. The mean age of the patients was 9.5 ± 5.3 years, and most patients were found to be in the 
middle 10s (43.9%). Among the CKD patients, male patients were more frequent than female patients 
regardless of age (n = 299 versus n = 138). The most common disease leading to CKD was renal 
hypoplasia (41.4%), while 66 patients had kidney dysplasia with/out vesico-ureteral reflux (VUR) 
(15.1%), and 27.7% had glomerulonephritis. Overall, 27.2% of patients were in CKD stage 2, while a 
minority (3.9%) had CKD stage 5 in a pre-dialysis state. 
Table 1. Baseline demographics of the chronic kidney disease (CKD) patient cohort.  
Variable 
Total Patients (%) 
(n = 437)  
Age (years) 9.5 ± 5.3 
0–2 years 43 (9.8) 
2–6 years 77 (17.6) 
6–12 years 125 (28.6) 
12–17 years 192 (43.9) 
Sex (male/female) 299/138 
Disease preceding CKD   
Primary glomerulopathy * 61 (14.0) 
Secondary glomerulopathy * 60 (13.7) 
Kidney dysplasia with/out vesico-ureteral reflux 66 (15.1) 
Hypoplasia 181 (41.4) 
Other 69 (15.8) 
CKD stages   
I 79 (18.1) 
II 119 (27.2) 
IIIa ※ 74 (16.9) 
IIIb ※ 71 (16.3) 
IV 77 (17.6) 
V 17 (3.9) 
Birth weight (kg)  3.0 ± 0.7 
Birth age (weeks)  38.3 ± 3.1 
Disease duration (years) † 5.7 ± 4.7 
Duration of aggravated renal function (years) ‡ 2.9 ± 3.4 
Numerical values are reported as n (%); CKD, chronic kidney disease; n, number of patients. * More 
detailed data are described in supplementary Table S1; ※ CKD stage III is divided into subgroup 
stage IIIa and IIIb according to the eGFR (estimated glomerular filtration rate), stage IIIa is an eGFR 
between 45 and 59 and Stage 3b is an eGFR between 30 and 44; † Disease duration refers to the years 
between the date of the baseline data collection and the CKD diagnosis date; ‡ Duration of aggravated 
renal function means the years between the date of the baseline data collection and the date of onset 
of the preceding disease to CKD. 
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38 (22.1) 33 (12.6)
IV 54 (31.4) 21 (8.0)
V 14 (9.9) 3 (1.1)
Weight (kg) 171 255 0.036 ††
Low weight 60 (35.1) 61 (23.9)
Normal 107 (62.6) 184 (72.2)
Overweight 4 (2.3) 10 (3.9)
Height (cm) 171 255 0.058 †
Short stature 48 (28.1) 49 (19.2)
Normal 122 (71.4) 201 (78.8)
Tall stature 1 (0.6) 5 (2.0)
Hypertension 156 216
SBP hypertension 24 (15.4) 34 (15.7) 0.926 ††
DBP hypertension 43 (27.6) 39 (18.1) 0.029 ††
Proteinuria (mg/mg) 172 261 <0.001 ††
<0.5 69 (15.9) 162 (37.4)
≥0.5 103 (37.4) 99 (22.9)
Ferritin (ng/mL) 163 233 <0.001 ††
≥100 51 (31.3) 33 (14.2)
<100 112 (68.7) 200 (85.8)
Transferrin saturation (%) 170 253 0.694 ††
<20 54 (31.8) 85 (33.6)
≥20 116 (68.2) 168 (66.4)
Use of EPO stimulating agents 167 261 0.001 ††
Yes * 36 (21.6) 7 (2.7)
Iron supplementation treatment 171 261 0.001 ††
Yes ** 62 (36.3) 29 (11.1)
Use of renin-angiotensin system (RAS)
inhibitors 172 261 0.002 ††
Yes *** 110 (70.0) 123 (47.1)
Numerical values are reported as n (%); CKD, chronic kidney disease; n, number of patients; EPO, erythropoietin;
SBP, systolic blood pressure; DBP, diastolic blood pressure;
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(15.1%), and 2 .7% had glomerulonephritis. Overall, 27.2% of patients were in CKD stage 2, while a 
minority (3.9%) had CKD stage 5 in a pre-dialysis state. 
Table 1. Baseline demographics of the chronic kidney disease (CKD) patient cohort.  
Variable 
Total Patients (%) 
(n = 437)  
Age (years) 9.5 ± 5.3 
0–2 years 43 (9.8) 
2–6 years 77 (17.6) 
6–12 y ars 125 (28.6) 
12–17 years 192 (43.9) 
Sex (male/female) 299/138 
Disease preceding CKD   
Primary glomerulopathy * 61 (14.0) 
Secondary glomerulopathy * 60 (13.7) 
Kidney dysplasia with/out vesico-ureteral reflux 66 (15.1) 
Hypoplasia 181 (41.4) 
Other 69 (15.8) 
CKD stages   
I 79 (18.1) 
II 119 (27.2) 
IIIa ※ 74 (16.9) 
IIIb ※ 71 (16.3) 
IV 77 (17.6) 
V 17 (3.9) 
Birth weight (kg)  3.0 ± 0.7 
Birth age (weeks)  38.3 ± 3.1 
Disease duration (years  † 5.7 ± 4.7 
Duration of aggravated renal function (years) ‡ 2.9 ± 3.4 
Numerical values are reported as n (%); CKD, chronic kidney disease; n, number of patients. * More 
detailed data are described in supplementary Table S1; ※ CKD stage III is divided into subgroup 
stage IIIa and IIIb according to the eGFR (estimated glomerular filtration rate), stage IIIa is an eGFR 
between 45 and 59 and Stage 3b is an eGFR between 30 and 44; † Disease duration refers to the years 
between the date of the baseline data collection and the CKD diagnosis date; ‡ Duration of aggravated 
renal function means the years between the date of the baseline data collection and the date of onset 
of the preceding disease to CKD. 
D stage III is divi ed into subgro p stage IIIa and
IIIb according to the eGFR (estimated glomerular filtration rate), stage IIIa is an eGFR between 45 and 59 and Stage
3b is an eGFR between 30 and 44; * EPO stimulating agents: Epoetin alfa, Epoetin beta; ** Iron agents: any agent
including intravenous or oral intake; *** AS inhibitors: Angiotensin-converting enzyme inhibitors, angiotensin II
receptor blockers; † Statistically significant differences were demonstrated using Fisher’s exact test; †† Statistically
significant differences were demonstrated using the Chi-square test.
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Patients with CKD showed a bimodal distribution with low hemoglobin levels at ages 0–2 years
(11.14 ± 1.64 g/dL) and at ages 6–12 years (11.65 ± 1.79 g/dL) (Table 3). Hemoglobin levels decreased
significantly with increases in CKD stage, with a mean of 12.22 ± 1.94 g/dL (p < 0.001) (Table 4).
Hemoglobin distribution according to the disease preceding CKD is summarized in Table 5. Patients
with primary glomerulonephritis had significantly lower hemoglobin levels, compared to other kidney
diseases (p = 0.003).
In children with CKD who did not receive ESA, anemia was associated with older age (OR 1.075,
p < 0.001), low weight (OR 0.853, p = 0.008), low body mass index (BMI) z-score (OR 0.779, p = 0.003),
existence of glomerulonephritis (OR 3.263, p < 0.001), high levels of ionized parathyroid hormone
(iPTH) (OR 1.007, p < 0.001) and serum phosphorus (OR 1.773, p < 0.001), low serum albumin (OR 0.498,
p < 0.001) and calcium (OR 0.494, p < 0.001) levels, and low eGFR (OR 0.966, p < 0.001) in the
univariate logistic regression. The multiple logistic regression analysis revealed the existence of
glomerulonephritis (OR 3.263, p < 0.001) to be an independent risk factor associated with anemia in
children with CKD (Table 6).
Anemia correlated positively with changes in BMI z-score (r = 0.434, p < 0.001), weight (r = 0.324,
p < 0.001), serum albumin (r = 0.288, p < 0.001), and cholesterol (r = 0.398, p < 0.001), but correlated
negatively with serum calcium (r = −0.403, p < 0.001), iPTH (r = −0.616, p < 0.001), ferritin (r = −0.119,
p = 0.019), and transferrin saturation (r = −0.253, p < 0.001) (Table 7).
3.3. CKD Patients with Iron Deficiency
Characteristics of the CKD patients with iron deficiency are summarized in Table 8. Age (p = 0.002),
existence of glomerulonephritis as a preceding disease (p = 0.017), systolic blood pressure (p = 0.036),
and presence of comorbidities (p = 0.009) were significantly higher in patients with iron deficiency than
in those without. Other variables, including sex, weight, CKD stages, and use of iron supplementation
agents, did not differ between the two groups.
In CKD patients with iron deficiency, ferritin levels were significantly lower in the 2–6 year-old
age group (44.86 ± 53.08 ng/mL, p < 0.001); however, the lowest age group with transferrin saturation
was 0–2 years (21.68 ± 13.51%, p = 0.001) (Table 3). Interestingly, ferritin levels showed a significant
increase as the CKD stage increased (p < 0.001). In contrast, there were no significant differences in
transferrin saturation across the CKD stages (Table 4). As shown in Table 5, kidney dysplasia with/out
VUR, pyelonephritis, and children with interstitial nephritis had the lowest ferritin levels, compared to
other kidney diseases (55.79 ± 43.59 ng/mL, p < 0.001). Transferrin saturation showed a significantly
lower percentage in the congenital, hereditary, cystic disease group (24.28 ± 11.44%, p < 0.001).
In children with CKD who did not take iron supplements, iron deficiency was associated with
younger age (OR 0.908, p < 0.001), lower hemoglobin (OR 0.843, p = 0.015), and lower ferritin (OR 0.980,
p < 0.001) levels in the univariate logistic regression analysis. The multiple logistic regression analysis
demonstrated that an increased BMI z-score (OR 1.318, p = 0.024) and decreased iPTH (OR 0.993,
p = 0.007), hemoglobin (OR 0.693, p < 0.001), and ferritin (OR 0.976, p < 0.001) levels were risk factors
associated with iron deficiency in children with CKD (Table 9).
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Table 3. Hemoglobin, transferrin saturation, and ferritin levels stratified by age in the CKD cohort.
Total 0–2 Years 2–6 Years 6–12 Years 12–18 Years
P Value
(n = 437) (n = 43) (n = 77) (n = 125) (n = 192)
Hemoglobin (g/dL) 12.15 ± 1.94 11.14 ± 1.64 12.34 ± 1.43 11.65 ± 1.79 12.55 ± 2.12 <0.001 *
Male 12.37 ± 2.01 11.35 ± 1.92 12.58 ± 1.34 11.6 ± 1.8 13.04 ± 2.11 <0.001 *
Female 11.9 ± 1.74 11.43 ± 1.7 12.39 ± 1.48 11.85 ± 1.71 11.8 ± 1.87 0.227 *
Transferrin saturation (%) 27.86 ± 16.49 21.68 ± 13.51 23.05 ± 10.87 29.84 ± 21.63 29.25 ± 14.15 0.001 *
Male 27.47 ± 16.02 21.35 ± 10.89 23.38 ± 11.51 29.19 ± 23.02 29.02 ± 11.53 0.001 *
Female 27.68 ± 15.92 20.66 ± 15.99 22.9 ± 9.96 30.23 ± 13.92 30.31 ± 18.53 0.04 *
Ferritin (ng/mL) 99.47 ± 211.51 96.2 ± 114.5 44.86 ± 53.08 111.03 ± 270.89 113.12 ± 217.17 <0.001 *
Male 93.43 ± 172.19 105.65 ± 129.99 49.6 ± 65.59 105.02 ± 262.15 97.21 ± 114.86 <0.001 *
Female 112.75 ± 279.6 76.44 ± 73.84 38.1 ± 26.41 128.25 ± 298.59 148.9 ± 351.2 0.016 *
CKD, chronic kidney disease; n, number of patients; * Statistical significance was demonstrated using the Kruskal–Wallis test.
Table 4. Hemoglobin, transferrin saturation, and ferritin levels stratified by CKD stage.
Total (n = 437) I (n = 79) II (n = 119) IIIa
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2.3. Statistical Analyses 
Categorical variables expressed as percentages were compared between groups with the Chi-
square test and Fisher’s exact test. Continuous variables were expressed as a mean ± standard 
deviation and analyzed by the Kruskal–Wallis test. A logistic regression analysis was conducted to 
determine the odds ratios (ORs) and confidence intervals (CIs) of associated risk factors for anemia 
and iron deficiency in the cohort. The correlations among characteristics of anemia in the cohort were 
analyzed with a Pearson r correlation. All statistical analyses were performed using SAS statistical 
software (SAS system for Windows, version 9.4; SAS institute, Cary, NC). 
3. Results 
3.1. Baseline Characteristics of Overall CKD Cohort 
The demographic characteristics and clinical manifestations of patients with CKD are shown in 
Table 1. The mean age of the patients was 9.5 ± 5.3 years, and most patients were found to be in the 
middle 10s (43.9%). Among the CKD patients, male patients were more frequent than female patients 
regardless of age (n = 299 versus n = 138). The most common disease leading to CKD was renal 
hypoplasia (41.4%), while 66 patients had kidney dysplasia with/out vesico-ureteral reflux (VUR) 
(15.1%), and 27.7% had glomerulonephritis. Overall, 27.2% of patients were in CKD stage 2, while a 
minority (3.9%) had CKD stage 5 in a pre-dialysis state. 
Table 1. Baseline demographics of the chronic kidney disease (CKD) patient cohort.  
Variable 
Total Patients (%) 
(n = 437)  
Age (years) 9.5 ± 5.3 
0–2 years 43 (9.8) 
2–6 years 77 (17.6) 
6–12 years 125 (28.6) 
12–17 years 192 (43.9) 
Sex (male/female) 299/138 
Disease preceding CKD   
Primary glomerulopathy * 61 (14.0) 
Secondary glomerulopathy * 60 (13.7) 
Kidney dysplasia with/out vesico-ureteral r flux 6  ( 5.1) 
Hypoplasia 181 (41.4) 
Other 69 (15.8) 
CKD stages   
I 79 (18.1) 
II 119 (27.2) 
IIIa ※ 74 (16.9) 
IIIb ※ 71 (16.3) 
IV 77 (17.6) 
V 17 (3.9) 
Birth weight (kg)  3.0 ± 0.7 
Birth age (weeks)  38.3 ± 3.1 
Disease duration (years) † 5.7 ± 4.7 
Duration of aggravated renal function (years) ‡ 2.9 ± 3.4 
Numerical values are reported as n (%); CKD, chronic kidney disease; n, number of patients. * More 
detailed data are described in supplementary Table S1; ※ CKD stage III is divided into subgroup 
stage IIIa and IIIb according to the eGFR (estimated glomerular filtration rate), stage IIIa is an eGFR 
between 45 and 59 and Stage 3b is an eGFR between 30 and 44; † Disease duration refers to the years 
between the date of the baseline data collection and the CKD diagnosis date; ‡ Duration of aggravated 
renal function means the years between the date of the baseline data collection and the date of onset 
of the preceding disease to CKD. 
(n = 74) b
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3. Results 
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Table 1. Baseline demographics of the chronic kidney disease (CKD) patient cohort.  
Variable 
Total Patients (%) 
(n = 437)  
Age (years) 9.5 ± 5.3 
0–2 years 43 (9.8) 
2–6 years 77 (17.6) 
6–12 years 125 (28.6) 
12–17 years 192 (43.9) 
Sex (male/female) 299/138 
Disease preceding CKD   
Primary glomerulopathy * 61 (14.0) 
Secondary glomerulopathy * 60 (13.7) 
Kidney dysplasia with/out vesico-ureteral reflux 66 ( 5. ) 
Hypoplasia 181 (41.4) 
Other 69 (15.8) 
CKD stages   
I 79 (18.1) 
II 119 (27.2) 
IIIa ※ 74 (16.9) 
IIIb ※ 71 (16.3) 
IV 77 (17.6) 
V 17 (3.9) 
Birth weight (kg)  3.0 ± 0.7 
Birth age (weeks)  38.3 ± 3.1 
Disease duration (years) † 5.7 ± 4.7 
Duratio  of aggravated renal function (years) ‡ 2.9 ± 3.4 
Numerical v lues are reported as n (%); CKD, chronic kidney disease; , numbe  of patients. * More 
tailed data are described in supplementary T ble S1; ※ CKD stage III is divided into subgroup 
stage IIIa and IIIb according to the eGFR (estimated glomerular filtration rat ), stage IIIa is an eGFR 
between 45 and 59 and Stage 3b is an eGFR betwe n 30 and 44; † Disease duration refers to the years 
between the date of th  baseline data collect on and the CK  di gnosis date; ‡ Duration of aggravated 
renal function means  years between the date of the baseline data collection and the date of onset 
of th preceding disease to CKD. 
(n = 71) IV (n = 77) V (n = 17) P Value
Hemoglobin (g/dL) 12.22 ± 1.94 13.1 ± 1.46 13.03 ± 1.73 12.34 ± 1.75 11.75 ± 1.77 10.85 ± 1.72 10.14 ± 2.17 <0.001 *
Male 12.37 ± 2.01 13.41 ± 1.49 13.21 ± 1.8 12.48 ± 1.67 11.84 ± 1.82 10.84 ± 1.8 10.38 ± 2.18 <0.001 *
Female 11.9 ± 1.74 12.39 ± 1.14 12.65 ± 1.46 12.05 ± 1.93 11.58 ± 1.69 10.87 ± 1.56 9.58 ± 2.31 <0.001 *
Transferrin saturation (%) 27.54 ± 15.97 27.87 ± 23.68 26.06 ± 12.56 26.88 ± 14.12 29.34 ± 13.66 27.19 ± 13.29 33.19 ± 20.44 0.449 *
Male 27.47 ± 16.02 28.65 ± 26.55 27.43 ± 12.57 25.55 ± 12.13 28.32 ± 10.63 26.74 ± 13.34 30.32 ± 15.85 0.722 *
Female 27.68 ± 15.92 25.91 ± 14.51 23.03 ± 12.19 29.58 ± 17.48 31.23 ± 18.06 28.25 ± 13.41 40.1 ± 29.93 0.338 *
Ferritin (ng/mL) 99.47 ± 211.51 53.27 ± 51.2 81.58 ± 135.93 83.15 ± 131.44 122.96 ± 335.38 139.63 ± 284.45 201.81 ± 231.99 <0.001 *
Male 93.43 ± 172.19 60.25 ± 57.3 78.42 ± 75.42 77 ± 111.18 61.98 ± 59.64 171.92 ± 342.43 191.83 ± 263.38 <0.001 *
Female 112.75 ± 279.6 33.51 ± 16.37 88.6 ± 218.8 96.26 ± 168.89 239.62 ± 555.72 75.03 ± 60.18 225.78 ± 153.27 0.013 *
CKD, chronic kidney disease; n, number of patients;
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2.3. Statistical Analyses 
Categorical variables expressed as percentages were compared between groups with the Chi-
square test and Fisher’s exact test. Continuous variables were expressed as a mean ± standard 
deviation and analyzed by the Kruskal–Wallis test. A logistic regression analysis was conducted to 
determine the odds ratios (ORs) and confidence intervals (CIs) of associated risk factors for anemia 
and iron deficiency in the cohort. The correlations among characteristics of anemia in the cohort were 
analyzed with a Pearson r correlation. All statistical analyses were performed using SAS statistical 
software (SAS system for Windows, version 9.4; SAS institute, Cary, NC). 
3. Results 
3.1. Baseline Characteristics of Overall CKD Cohort 
The demographic characteristics and clinical manifestations of patients with CKD are shown in 
Table 1. The mean age of the patients was 9.5 ± 5.3 years, and most patients were found to be in the 
middle 10s (43.9%). Among the CKD patients, male patients were more frequent than female patients 
regardless of age (n = 299 versus n = 138). The most common disease leading to CKD was renal 
hypoplasia (41.4%), while 66 patients had kidney dysplasia with/out vesico-ureteral reflux (VUR) 
(15.1%), and 27.7% had glomerulonephritis. Overall, 27.2% of patients were in CKD stage 2, while a 
minority (3.9%) had CKD stage 5 in a pre-dialysis state. 
Table 1. Baseline demographics of the chronic kidney disease (CKD) patient cohort.  
Variable 
Total Patients (%) 
(n = 437)  
Age (years) 9.5 ± 5.3 
0–2 years 43 (9.8) 
2–6 years 77 (17.6) 
6–12 years 25 (28.6) 
12–17 years 192 (43.9) 
Sex (male/female) 299/138 
Disease preceding CKD   
Primary glomerulopathy * 61 (14.0) 
Secondary glomerulopathy * 60 (13.7) 
Kidney dysplasia with/out vesico-ureteral reflux 66 (15.1) 
Hypoplasia 181 (41.4) 
Other 69 (15.8) 
CKD stages   
I 79 (18.1) 
II 119 (27.2) 
IIIa ※ 74 (16.9) 
IIIb ※ 71 (16.3) 
IV 77 (17.6) 
V 17 (3.9) 
Birth weight (kg)  3.0 ± 0.7 
Birth age (weeks)  38.3 ± 3.1 
Disease duration (years) † 5.7 ± 4.7 
Duration of aggravated renal function (years) ‡ 2.9 ± 3.4 
Numerical values are reported as n (%); CKD, chronic kidney disease; n, number of patients. * More 
detailed data are describe  in supplementary Table S1; ※ CKD stage III is divided into subgroup 
stage IIIa and IIIb according to the eGFR (estimated glomerular filtration rate), stage IIIa is an eGFR 
between 45 and 59 and Stage 3b is an eGFR between 30 and 44; † Disease duration refers to the years 
between the date of the baseline data collection and the CKD diagnosis date; ‡ Duration of aggravated 
renal function means the years between the date of the baseline data collection and the date of onset 
of the preceding disease to CKD. 
D stage III is divi ed into subgroup stage IIIa and IIIb according to the eGFR (estimated glomerular filtration rate), stage IIIa is an
eGFR between 45 and 59 and Stage 3b is an eGFR between 30 and 44; * Statistical significance was demonstrated using the Kruskal–Wallis test.
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(n = 69) P Value
Hemoglobin (g/dL) 12.22 ± 1.94 11.39 ± 1.94 12.3 ± 1.5 12.77 ± 1.87 12.29 ± 1.88 12.18 ± 2.29 0.003 *
Male 12.37 ± 2.01 11.64 ± 2.09 12.41 ± 1.65 12.94 ± 1.84 12.36 ± 1.92 12.34 ± 2.46 0.043 †
Female 11.9 ± 1.74 10.92 ± 1.55 12.14 ± 1.26 11.81 ± 1.83 12.15 ± 1.79 11.9 ± 1.97 0.097
Transferrin saturation (%) 27.54 ± 15.97 36.44 ± 27.36 27.66 ± 13.13 25.92 ± 10.6 24.28 ± 11.44 29.86 ± 16.6 <0.001 *
Male 27.47 ± 16.02 36.31 ± 30.69 27.47 ± 11.12 26.77 ± 10.45 24.55 ± 11.74 28.49 ± 14.1 0.009 *
Female 27.68 ± 15.92 36.69 ± 20.01 27.93 ± 15.93 21.25 ± 10.77 23.73 ± 10.85 32.54 ± 20.75 0.056
Ferritin (ng/mL) 99.47 ± 211.51 90.08 ± 77.22 92.98 ± 183.59 55.79 ± 43.59 70.03 ± 102.28 242.3 ± 460.64 <0.001 *
Male 93.43 ± 172.19 101.24 ± 87.55 70.11 ± 64.22 59.46 ± 45.55 76.02 ± 115.35 204.69 ± 387.22 <0.001 *
Female 112.75 ± 279.6 67.19 ± 43.32 127.8 ± 280.81 34.19 ± 19.77 57.59 ± 66.85 310.36 ± 574.81 0.003 *
CKD, chronic kidney disease; n, number of patients; GN, glomerulonephritis; RN, kidney dysplasia with/out vesico-ureteral reflux; PN, pyelonephritis, IN, interstitial nephritis; CG,
congenital disease; HD, hereditary disease; CD, cystic disease; * Statistical significance was demonstrated using the Kruskal–Wallis test; † Statistical significance was demonstrated using
the Anova test.
Table 6. Associated risk factors for anemia in patients with CKD who did not take erythropoietin-stimulating agents.
Univariate Logistic Regression in Anemia Patients Multivariable Logistic Regression in Anemia Patients
Unadjusted OR (95% CI) P-Value Adjusted OR (95% CI) P Value
Age 1.075 (1.031, 1.121) 0.0006 - -
Weight z-score 0.853 (0.758, 0.960) 0.0081 - -
Height z-score 0.901(0.79, 1.029) 0.1247 - -
BMI z-score 0.779 (0.661, 0.918) 0.0029 - -
Birth age 1.132 (1.039, 1.233) 0.0046 - -
Glomerulonephritis 3.263 (1.905, 5.590) <0.0001 3.263 (1.905, 5.590) <0.0001
Hypertension 1.184 (0.731, 1.915) 0.4928 - -
Serum albumin 0.498 (0.355, 0.698) <0.0001 - -
eGFR 0.966 (0.957, 0.975) <0.0001 - -
iPTH 1.007 (1.004, 1.011) <0.0001 - -
Serum Ca 0.494 (0.389, 0.628) <0.0001 - -
Serum P 1.773 (1.352, 2.324) <0.0001 - -
Urine protein creatinine ratio 1.001 (0.968, 1.035) 0.9482 - -
Hemoglobin 0.138 (0.091, 0.208) <0.0001 - -
Ferritin 1.001 (1.000, 1.003) 0.0667 - -
Transferrin saturation 1.003 (0.990, 1.016) 0.6548 - -
Iron supplementation use ** 3.652 (2.058, 6.482) <0.0001 - -
CKD, chronic kidney disease; OR, odds ratio; CI, confidence interval; BMI, body mass index; GFR, estimated glomerular filtration rate; iPTH, ionized parathyroid hormone; Ca, serum
calcium; P, serum phosphorus; ** Iron agents: any agents including intravenous or oral intake.
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Table 7. Correlations among key characteristics of anemic children in the CKD cohort.





























































































































































































































































CKD, chronic kidney disease; Hb, hemoglobin; Reti, reticulocyte count; Tran sat, transferrin saturation; iPTH, ionized parathyroid hormone; eGFR, estimated glomerular filtration rate; Alb,
albumin; Ca, serum calcium; P, serum phosphorus; Chole, cholesterol; BMI-z, body mass index z-score. The first column of each angle is the r-value and the second column is the p-value.
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Table 8. Comparisons of characteristics of patients with iron deficiency in the CKD cohort.
Variable Patients with Iron Deficiency(n = 107)
Patients without Iron Deficiency
(n = 290) P Value
Age (years) 107 290 0.002 ††
0–2 years 16 (15.0) 18 (6.2)
2–6 years 25 (23.4) 42 (14.5)
6–12 years 30 (28.0) 85 (29.3)
12–17 years 36 (33.6) 145 (50.0)
Sex (male/female) 68/39 205/85 0.173 ††
Disease preceding CKD 95 254 0.017 ††
Glomerulonephritis 12 (12.6) 62 (24.4)
Non-glomerulonephritis 83 (87.3) 192 (75.6)
CKD stages 107 290 0.057 ††
I 23 (21.5) 46 (15.9)
II 28 (26.2) 75 (25.9)
IIIa
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2.3. Statistical Analyses 
Categorical variables expressed as percentages were compared between groups with the Chi-
square test and Fisher’s exact test. Continuous variables were expressed as a mean ± standard 
deviation and analyzed by the Kruskal–Wallis test. A logistic regression analysis was conducted to 
determine the odds ratios (ORs) and confidence intervals (CIs) of associated risk factors for anemia 
and iron deficiency in the cohort. The correlations among characteristics of anemia in the cohort were 
analyzed with a Pearson r correlation. All statistical analyses were performed using SAS statistical 
software (SAS system for Windows, version 9.4; SAS institute, Cary, NC). 
3. Results 
3.1. Baseline Characteristics of Overall CKD Cohort 
The demographic characteristics and clinical manifestations of patients with CKD are shown in 
Table 1. The mean age of the patients was 9.5 ± 5.3 years, and most patients were found to be in the 
middle 10s (43.9%). Among the CKD patients, male patients were more frequent than female patients 
regardless of age (n = 299 versus n = 138). The most common disease leading to CKD was renal 
hypoplasia (41.4%), while 66 patients had kidney dysplasia with/out vesico-ureteral reflux (VUR) 
(15.1%), and 27.7% had glomerulonephritis. Overall, 27.2% of patients were in CKD stage 2, while a 
minority (3.9%) had CKD stage 5 in a pre-dialysis state. 
Table 1. Baseline demographics of the chronic kidney disease (CKD) patient cohort.  
Variable 
Total Patients (%) 
(n = 437)  
Age (years) 9.5 ± 5.3 
0–2 years 43 (9.8) 
2–6 years 77 (17.6) 
6–12 years 125 (28.6) 
12–17 years 192 (43.9) 
Sex (male/female) 299/138 
Disease preceding CKD   
Primary glomerulopathy * 61 (14.0) 
Secondary glomerulopathy * 60 (13.7) 
Kidney dysplasia with/out vesico-ureteral reflux 66 (15.1) 
Hypoplasia 181 (41.4) 
Other 69 (15.8) 
CKD stages   
I 79 (18.1) 
II 119 (27.2) 
IIIa ※ 74 (16.9) 
IIIb ※ 71 (16.3) 
IV 77 (17.6) 
V 17 (3.9) 
Birth weight (kg)  3.0 ± 0.7 
Birth age (weeks)  38.3 ± 3.1 
Disease duration (years) † 5.7 ± 4.7 
Duration of aggravated renal function (years) ‡ 2.9 ± 3.4 
Numerical values are reported as n (%); CKD, chronic kidney disease; n, number of patients. * More 
detailed data are described in supplementary Table S1; ※ CKD stage III is divided into subgroup 
stage IIIa and IIIb according to the eGFR (estimated glomerular filtration rate), stage IIIa is an eGFR 
between 45 and 59 and Stage 3b is an eGFR between 30 and 44; † Disease duration refers to the years 
between the date of the baseline data collection and the CKD diagnosis date; ‡ Duration of aggravated 
renal function means the years between the date of the baseline data collection and the date of onset 
of the preceding disease to CKD. 
26 (24.3) 46 (15.9)
IIIb
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2.3. Statistical Analyses 
Categorical variables expressed as percentages were compared between groups with the Chi-
square test and Fisher’s exact test. Continuous variables were expressed as a mean ± standard 
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determine the odds ratios (ORs) and confidence intervals (CIs) of associated risk factors for anemia 
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The demographic characteristics and clinical manifestations of patients ith CKD are shown in 
Table 1. The mean age of the patients was 9.5 ± 5.3 years, and most patients were found to be in the 
middle 10s (43.9%). Among the CKD patients, male patients were more frequent than female patients 
regardless of age (n = 299 versus n = 138). The most common disease leading to CKD was renal 
hypoplasia (41.4 ), while 66 patients had kidney dysplasia with/out vesico-ureteral reflux (VUR) 
(15.1%), and 27.7% had glomerulonephritis. Overall, 27.2% of patients were in CKD stage 2, while a 
minority (3.9%) had CKD stage 5 in a pre-dialysis state. 
Table 1. Baseline demographics of the chronic kidney disease (CKD) patient cohort.  
Variable 
Total Patients (%) 
(n = 437)  
Age (years) 9.5 ± 5.3 
0 2  43 (9.8) 
2 6 years 77 (17.6) 
6–12 years 25 (28.6) 
12–17 years 192 (4 .9) 
Sex (male/female) 299/138 
Disease preceding CKD   
Primary glomerulopathy * 1 ( 4.0) 
Secondar  glomerulopathy * 0 ( 3.7) 
Kidney dysplasia with/out vesico-ureteral reflux 66 (15.1) 
Hypoplasia 181 (41.4) 
Other 69 (15.8) 
CKD stages   
I 79 (18.1) 
II 119 (27.2) 
IIIa  4 ( .9) 
IIIb ※ 1 ( 6.3) 
IV 77 (17.6) 
V 17 (3.9) 
irt  weight ( g)  3.0 ± 0.7 
Birth age (weeks)  38.3 ± 3.1 
Disease duration (years) † 5.7 ± 4.7 
Duration of aggravated renal function (years) ‡ 2.9 ± 3.4 
Numerical values are reported as n (%); CKD, chronic kidney disease; n, number of patients. * More 
detailed data are described in supplementary Table S1; ※ CKD stage III is divided into subgroup 
stage IIIa and IIIb according to the eGFR (estimated glomerular filtration rate), stage IIIa is an eGFR 
bet een 45 and 59 and Stage 3b is an eGFR between 30 and 44; † Disease duration refers to the years 
between the date of the baseline data collection and the CKD diagnosis date; ‡ Duration of aggravated 
renal function means the years between the date of the baseline data collection and the date of onset 
of the preceding disease to CKD. 
15 (14.0) 50 (17.2)
IV 14 (13.1) 57 (20.0)
V 1 (1.0) 16 (5.5)
Weight (kg) 105 285 0.213 ††
Low weight 33 (30.8) 76 (26.7)
Normal 66 (61.7) 201 (70.5)
Overweight 6 (5.6) 8 (2.8)
Height (cm) 105 285 0.835 †
Short stature 25 (23.8) 61 (21.4)
Normal 78 74.3) 219 (76.8)
Tall stature 2 (1.9) 5 (1.8)
Hypertension 91 251
SBP hypertension 20 (22.2) 32 (12.7) 0.036 ††
DBP hypertension 16 (17.6) 60 (23.9) 0.214 ††
Comorbidity 107 290 0.009 ††
Present 71 (66.4) 150 (51.7)
Absent 36 (33.6) 140 (48.3)
Iron supplementation treatment 107 289 0.692 ††
Yes ** 21 (19.6) 62 (21.5)
Numerical values are reported as n (%); CKD, chronic kidney disease; n, number of patients; EPO, erythropoietin; SBP, systolic blood pressure; DBP, diastolic blood pressure;
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Table 1. Baseline demographics of the chronic kidney disease (CKD) patient cohort.  
Variable 
Total Patients (%) 
(n = 437)  
Age (years) 9.5 ± 5.3 
0–2 years 43 (9.8) 
2–6 years 77 (17.6) 
6–12 years 125 (28.6) 
12–17 years 192 (43.9) 
Sex (male/female) 299/138 
Disease preceding CKD   
Primary glomerulopathy * 61 (14.0) 
Secondary glomerulopathy * 60 (13.7) 
Kidney dysplasia with/out vesico-ureteral reflux 66 (15.1) 
Hypoplasia 181 (41.4) 
Other 69 (15.8) 
CKD stages   
I 79 (18.1) 
II 119 (27.2) 
IIIa ※ 74 (16.9) 
IIIb ※ 71 (16.3) 
IV 77 (17.6) 
V 17 (3.9) 
Birth weight (kg)  3.0 ± 0.7 
Birth age (weeks)  38.3 ± 3.1 
Disease duration (years) † 5.7 ± 4.7 
Duration of aggravated renal function (years) ‡ 2.9 ± 3.4 
Numerical values are reported as n (%); CKD, chronic kidney disease; n, number of patients. * More 
detailed data are described in supplementary Table S1; ※ CKD stage III is divided into subgroup 
stage IIIa and IIIb according to the eGFR (estimated glomerular filtration rate), stage IIIa is an eGFR 
between 45 and 59 and Stage 3b is an eGFR between 30 and 44; † Disease duration refers to the years 
between the date of the baseline data collection and the CKD diagnosis date; ‡ Duration of aggravated 
renal function means the years between the date of the baseline data collection and the date of onset 
of the preceding disease to CKD. 
CKD stage
III is divided into subgroup stage IIIa and IIIb according to the eGFR (estimated glomerular filtration rate), stage IIIa is an eGFR between 45 and 59 and Stage 3b is an eGFR between 30
and 44; ** Iron agents: Any agent including intravenous or oral intake; † Statistically significant differences were demonstrated using Fisher’s exact test; †† Statistical significance was
demonstrated using the Chi-square test.
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Table 9. Associated risk factors for iron deficiency in patients with CKD who did not take iron supplements.
Univariate Logistic Regression in Iron Deficiency Patients Multivariable Logistic Regression in Iron Deficiency Patients
Unadjusted OR (95% CI) P-value Adjusted OR (95% CI) P Value
Age 0.908 (0.865, 0.954) 0.0001 - -
Weight z-score 1.041 (0.895, 1.212) 0.6002 - -
Height z-score 1.002(0.847, 1.184) 0.9856
BMI z-score 1.148 (0.939, 1.403) 0.1783 1.318 (1.038, 1.675) 0.0235
Birth age 0.783 (0.545, 1.125) 0.1858 - -
Glomerulonephritis 0.569 (0.277, 1.168) 0.1243 - -
Hypertension 1.327 (0.752, 2.34) 0.3292 - -
Serum albumin 0.791 (0.543, 1.152) 0.2209 - -
eGFR 1.004 (0.996, 1.012) 0.3357 - -
iPTH 0.997 (0.993, 1.001) 0.107 0.993 (0.988, 0.998) 0.007
Serum Ca 1.008 (0.804, 1.264) 0.9467 - -
Serum P 1.09 (0.797, 1.493) 0.589 - -
Hemoglobin 0.843 (0.734, 0.967) 0.0145 0.693 (0.565, 0.85) 0.0004
Ferritin 0.980 (0.970, 0.989) <0.0001 0.976 (0.965, 0.987) <0.0001
Transferrin saturation 1.018 (0.990, 1.047) 0.2164 - -
Erythropoietin stimulating use ** 0.985 (0.255, 3.802) 0.9825 - -
CKD, chronic kidney disease; OR, odds ratio; CI, confidence interval; BMI, body mass index; GFR, glomerular filtration rate; iPTH, ionized parathyroid hormone; Ca, serum calcium; P,
serum phosphorus; ** Iron agents: any agents including intravenous or oral intake.
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4. Discussion
Anemia and iron deficiency are important complications in pediatric patients with CKD. The aim
of aggressive treatment of anemia is to avoid regular red blood cell transfusions and to improve the
quality of life, cognitive function, exercise capacity, and cardiovascular function of children [13]. The
best treatment options for anemia and iron deficiency are EPO-stimulating and iron supplementation
agents; nonetheless, their use in hemodialysis or peritoneal dialysis patients is known to be less
effective than that in adults [14]. Therefore, it is important to identify the status of anemia and iron
deficiency and to actively correct these in pediatric CKD patients.
KNOW-PedCKD is the first prospective pediatric CKD cohort study about the clinical
characteristics and prevalence of anemia and iron deficiency in Asia. In addition, this is the first
attempt to analyze risk factors for anemia in CKD children. Other pediatric CKD cohort studies, such
as CKiD or “The Functional Outcomes in Adolescent CKD study”, showed hemoglobin levels and only
in part reported the prevalence of anemia [15,16] In contrast, we performed comprehensive analyses
firstly in the pediatric area.
In our KNOW-PedCKD cohort study, the proportion of CKD patients with anemia was the lowest
at 2–5 years of age and then increased with older age. This result was comparable to that reported
in a previous study on a pediatric CKD cohort, NAPRTCS [1]. Thus, school-aged patients of ages
12–17 years with CKD are more likely to have anemia, making it is necessary for clinicians to detect
and treat anemia appropriately.
Individual studies, such as the ItalKid study [17], the British Association of Pediatric
Nephrology [18], and NAPRTCS [1,19], have reported the major causes of CKD. These studies suggest
that glomerulonephritis is the cause of end-stage renal disease (ESRD) in 20% of cases, while congenital
abnormalities of the kidney and urinary tract (CAKUT) occur in 50% of patients. Other congenital
diseases (CG) and hereditary diseases (HD) are considered causative in 20% of patients [1,17–19].
However, studies are lacking with regard to the relationships between diseases leading to
CKD and anemia. Interestingly, our study showed that anemia is more severe in patients with
glomerulonephritis than in those without. Recent evidence indicates that medications for the blockade
of the renin-angiotensin system (RAS) pathway to reduce proteinuria in glomerulonephritis modulate
erythropoiesis by regulation of angiotensin II signaling. Angiotensin II is involved in the proliferation
and differentiation of hematopoietic cell types, especially those of red blood cell lineage. Both
angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) induce
adverse effects related to decreased hematocrits [20]. Notwithstanding, iron deficiency was more
prominent in patients with non-glomerulonephritis (kidney dysplasia with/out VUR, pyelonephritis,
interstitial nephritis, congenital disease, hereditary disease, cystic disease, and others) (Table 8).
Ferritin increased as the CKD stage increased in our cohort. According to another report, ferritin
itself could act as an inflammatory marker [21]. In addition, according to Goyal et al., cytokines, such
as hepcidin and high-sensitivity C-reactive protein (hs-CRP), increase with increasing CKD stages
and ferritin showed a positive correlation with hepcidin [22]. This indicates that ferritin itself can
reflect inflammation in CKD patients. Because of the limited possibility to take blood in the pediatric
population, the fact that ferritin alone can detect both inflammation and iron deficiency in pediatric
CKD patients is a very important achievement in our study (Table 4).
The correlation results in our study indicated that anemia was positively correlated with low body
weight and BMI z-score (r = 0.324, p < 0.001 and r = 0.434, p < 0.001, respectively, Table 7). Although
it was not found to be an independent risk factor in the multivariate analysis, anemia and growth
are closely related in children with CKD. The underlying mechanism to explain low body weight
and BMI z-score with anemia are not very well-understood, although both may be related to CKD
progression. Low body weight and BMI z-score are considered to be results of the progression of
CKD, a combination of anorexia, increased energy expenditure, and muscle wasting [23], and anemia
has also been proposed to be associated with renal function itself. The relationship between eGFR
and anemia in childhood CKD has been studied in several studies [13,23]. Recently, Atkinson et al.
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analyzed data calculated using the CKiD and reported that, when the eGFR is reduced by 20%, the
hemoglobin level tends to decrease by 0.2–0.4 g/dL [15]. Similar to the CKiD results, the distribution
of anemia according to CKD stage in the KNOW-PedCKD cohort also increased according to higher
CKD stages (Table 2).
Hypertension is one of the major causes of CKD worldwide [24]. Our results indicated that
hypertension is associated with anemia based on diastolic blood pressure and iron deficiency based
on systolic blood pressure in children with CKD (Tables 2 and 8). However, in the univariate and
multivariate analyses, hypertension was not independently associated with anemia and iron deficiency
(Tables 6 and 9).
Anemia and iron deficiency are associated risk factors of CKD. Despite the established treatment
of anemia and iron deficiency in CKD patients, our result suggests the importance of simultaneous use
of EPO-stimulating agents and iron supplements as an effective treatment approach.
There are several limitations in this study. First, there could be unavailable data or information
of patients of the CKD cohort. Second, we could not include the patients’ diets and calorie intake in
this report. Third, we may not have excluded potential significant inter-study variations in the study
setting. In addition, it is not clear in CKD patients as to whether these indicators are the effect of CKD
itself or impact of anemia. We plan in future studies to examine the relationship between the impact of
anemia on quality of life, cognitive function, exercise capacity, and cardiovascular function and anemia
in the KNOW-pedCKD cohort.
5. Conclusions
This article is noteworthy because it is the first multicenter cohort study investigating the impact
of anemia in Korean pediatric patients with CKD and the first prospective pediatric CKD cohort
study in Asia. Supported by clinical evidence, our results indicate that anemia and iron deficiency
are key factors associated with CKD in pediatric patients. Understanding the multiple risk factors
causing anemia in CKD will improve the outcomes of children with CKD. Furthermore, ESA and
iron-replacement therapy have revolutionized the treatment of anemia in children and the negative
effects of anemia can be improved by these treatments. Additional studies are necessary to address the
issue of anemia in pediatric CKD according to each patient’s diet or quality of life in the future.
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